title: Auto-antibodies in prostate cancer: humoral immune response to antigenic determinants coded by the differentially expressed transcripts FLJ23438 and VAMP3.
abstract: BACKGROUND
  Here we evaluate auto-antibody response against two potential antigenic determinants of genes highly expressed in low Gleason Score prostate cancer (PC) tumor samples, namely FLJ23438 and VAMP3.
  
  
  METHODS
  RT-PCR assays were used to analyze mRNA expression profiles of FLJ23438 and VAMP3 transcripts. The auto-antibody response against FLJ23438 and VAMP3 recombinant proteins was tested by immunoblot assays using PC, benign prostate hyperplasia (BPH), healthy donors (HD), and other human cancers plasma samples.
  
  
  RESULTS
  Our data showed that 37% (10/27) and 7.4% (2/27) of PC plasma samples presented auto-antibodies against FLJ23438 and VAMP3, respectively. Only 8.3% (1/12) of BPH plasma samples were reactive for both auto-antibodies, while none (0/12) of HD plasma samples tested were reactive.
  
  
  CONCLUSIONS
  The prevalence of 37% of positive PC plasma samples for anti-FLJ23438 antibodies suggests that humoral immune response against this antigenic determinant could be a potential serum marker for this cancer.
authors.affiliation: Instituto Nacional de Câncer/MS, Coordenação de Pesquisa, Divisão de Medicina Experimental, Biologia Celular e Pesquisa Clínica, Rio de Janeiro, Brasil.
authors.forename: E R
authors.initials: ER
authors.lastname: Pontes
authors.forename: L C
authors.initials: LC
authors.lastname: Matos
authors.forename: E A
authors.initials: EA
authors.lastname: da Silva
authors.forename: L S
authors.initials: LS
authors.lastname: Xavier
authors.forename: B L
authors.initials: BL
authors.lastname: Diaz
authors.forename: I A
authors.initials: IA
authors.lastname: Small
authors.forename: E M
authors.initials: EM
authors.lastname: Reis
authors.forename: S
authors.initials: S
authors.lastname: Verjovski-Almeida
authors.forename: M A
authors.initials: MA
authors.lastname: Barcinski
authors.forename: E R P
authors.initials: ER
authors.lastname: Gimba
mesh_terms: D000230:Adenocarcinoma / Q000453:epidemiology / Q000276:immunology* / Q000503:physiopathology; D000368:Aged; D000941:Antigens / Q000235:genetics / Q000276:immunology; D001323:Autoantibodies / Q000097:blood*; D014408:Biomarkers, Tumor / Q000097:blood / Q000235:genetics / Q000276:immunology*; D001943:Breast Neoplasms; D002294:Carcinoma, Squamous Cell; D045744:Cell Line, Tumor; D015179:Colorectal Neoplasms; D004938:Esophageal Neoplasms; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008175:Lung Neoplasms; D008297:Male; D008875:Middle Aged; D016366:Open Reading Frames / Q000235:genetics; D011470:Prostatic Hyperplasia / Q000453:epidemiology / Q000276:immunology / Q000503:physiopathology; D011471:Prostatic Neoplasms / Q000453:epidemiology / Q000276:immunology* / Q000503:physiopathology; D012333:RNA, Messenger / Q000235:genetics; D012342:RNA, Small Nuclear / Q000235:genetics / Q000276:immunology; D011994:Recombinant Proteins / Q000235:genetics / Q000276:immunology; D016036:Seroepidemiologic Studies; D051040:Vesicle-Associated Membrane Protein 3 / Q000235:genetics / Q000276:immunology*
chemical_list: D000941:Antigens; D001323:Autoantibodies; D014408:Biomarkers, Tumor; D012333:RNA, Messenger; D012342:RNA, Small Nuclear; D011994:Recombinant Proteins; C405484:U2 small nuclear RNA; C494946:VAMP3 protein, human; D051040:Vesicle-Associated Membrane Protein 3